Cilostazol is a prescription medication classified under the cardiovascular therapeutic area, specifically used to improve blood flow in certain vascular conditions. It is available as a pill in strengths of 50 mg and 100 mg. In Hong Kong, cilostazol is regulated by the Department of Health and is prescribed by qualified healthcare professionals. The drug is also approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Cilostazol belongs to the class of phosphodiesterase-3 (PDE-3) inhibitors. By blocking the PDE-3 enzyme, it increases intracellular cyclic adenosine monophosphate (cAMP) levels in platelets and vascular smooth-muscle cells.
The combined antiplatelet and vasodilatory actions help relieve symptoms of reduced limb perfusion, particularly in the lower extremities. Onset of effect typically occurs within a few days, with steady-state concentrations reached after about 2 weeks of regular dosing.
Cilostazol is approved for the treatment of intermittent claudication-a condition marked by muscle pain in the legs during walking caused by peripheral arterial disease (PAD). It is indicated for adult patients who have adequate arterial blood flow to the legs but experience walking discomfort due to narrowed peripheral arteries.
Evidence from clinical studies has explored cilostazol for other vascular conditions, such as secondary prevention after ischemic stroke and certain forms of Raynaud’s phenomenon. These uses are not approved by regulatory agencies in Hong Kong, the United States, or Europe.
Off-label use requires medical supervision and individualized risk assessment.
Patients should disclose all medications, supplements, and herbal products to their healthcare provider before starting cilostazol.
Standard dosing:
Start with 50 mg taken twice daily (morning and evening) with a glass of water.
After 2 weeks, the dose may be increased to 100 mg twice daily if tolerated and if symptom control is insufficient.
Administration:
Swallow tablets whole; do not crush or chew.
Maintain consistent spacing between doses (approximately 12 hours).
Missed dose: Take the missed tablet as soon as remembered unless it is close to the next scheduled dose; do not double the dose.
Overdose: Symptoms may include severe headache, nausea, vomiting, and fainting. Seek emergency medical care; supportive measures are the mainstay of treatment. No specific antidote exists.
Discontinuation: No tapering is required for cilostazol, but patients should discuss cessation with their provider, especially if they have been on the medication for an extended period.
This article provides educational information about cilostazol and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Cilostazol is a phosphodiesterase-3 inhibitor that both inhibits platelet aggregation and dilates peripheral arteries, whereas aspirin primarily works by irreversibly inhibiting platelet cyclooxygenase. Cilostazol therefore improves walking distance in intermittent claudication, a benefit not provided by aspirin alone.
Most statins (e.g., atorvastatin, simvastatin) do not have a known interaction with cilostazol. However, any co-prescribed drug should be reviewed by your physician or pharmacist to confirm safety.
Cilostazol can be used in patients with mild to moderate renal impairment, but dosage adjustments may be necessary for severe kidney disease. Your healthcare provider will assess kidney function before prescribing.
Patients often report measurable improvement after 2 to 4 weeks of consistent therapy, with maximal benefit observed around 8 weeks.
Cilostazol primarily acts on peripheral vessels and has minimal effect on systemic blood pressure. However, individual responses can vary, and any significant changes should be reported to your clinician.
Yes, but carry the medication in its original labeled container, bring a copy of the prescription, and be aware of any import restrictions for prescription drugs in the destination country.
Cilostazol is itself a generic medication; various manufacturers may market it under different brand names, but the active ingredient remains the same.
A mild headache is common and often resolves on its own. If the headache is severe, persistent, or accompanied by visual changes, seek medical evaluation promptly, as it could signal a rare adverse reaction.
Ginkgo biloba has mild antiplatelet activity and could theoretically increase bleeding risk when combined with cilostazol. Discuss all herbal and supplement use with your healthcare provider.
Cilostazol can increase heart rate and myocardial oxygen demand, potentially worsening symptoms in patients with advanced heart failure (NYHA Class III-IV). This contraindication is based on clinical safety data.
